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Abstract We applied a coculture system for the genetic
manipulation of human B-lymphoid and myeloid progeni-
tor cells using murine bone marrow stromal cell support,
and investigated the effects of forced Pax5 expression in
both cell types. Cytokine-stimulated cord blood CD34
+
cells could be transduced at 85% efﬁciency and 95% cell
viability by a single 24-h infection with RD114-pseudo-
typed retroviral vectors, produced by the packaging cell
line Plat-F and bicistronic vector plasmids pMXs-Ig,
pMYs-Ig, or pMCs-Ig, encoding EGFP. Infected CD34
+
cells were seeded onto HESS-5 cells in the presence of
stem cell factor and granulocyte colony-stimulating factor,
allowing the extensive production of B progenitors and
granulocytic cells. We examined the cell number and
CD34, CD33, CD19, and CD20 lambda and kappa
expressions by ﬂow cytometry. Ectopic expression of Pax5
in CD34
+ cells resulted in small myeloid progenitors
coexpressing CD33 and CD19 and inhibited myeloid dif-
ferentiation. After 6 weeks, the number of Pax5-transduced
CD19
+ cells was 40-fold lower than that of control cells.
However, the expression of CD20 and the j/k chain on
Pax5-transduced CD19
+ cells suggests that the Pax5
transgene may not interfere with their differentiation. This
report is the ﬁrst to describe the effects of forced Pax5
expression in human hematopoietic progenitors.
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1 Introduction
The entry of lymphoid progenitors into the B-cell pathway
depends on the transcription factors E2A, EBF, and Pax5
[1]. B-cell development is closely associated with the
coordinated expression of phenotypic markers, such as B-
cell receptors, cytokine receptors, and their signal media-
tors [2–5]. Most of our knowledge on B-cell development
has come from extensive studies in mice; the examination
of human B-cell lymphopoiesis has been hampered by a
lack of appropriate experimental systems, although some
studies have been performed on tumor cells. Recently,
human B lymphopoiesis was partially reconstituted in
immuno-deﬁcient mice, and, several weeks after trans-
plantation, the major B-cell populations consisted of
immature CD19
+IgM
- B-cells [6]. However, such an in
vivo system is not amenable to the sequential observation
of B-cell differentiation, especially in the early stages.
For manipulating and observing human B-lymphoid
progenitors, the in vitro simulation of human B lympho-
poiesis by cultivating cord blood CD34
+ cells (CBCD34
+
cells) on a layer of murine, bone marrow stromal cells has
been described [7]. Studies have also reported the molec-
ular characterization of human hematopoietic progenitors
[8] and early T/NK and B-lymphoid progenitors [9],
derived from coculturing CBCD34
+ cells with murine
stromal cells. This culture method offers a limited, but
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scriptional regulation of both B-cell and granulocyte
differentiation via the ectopic expression or silencing of
lineage-speciﬁc transcription factors, including EBF, E2A,
Pax5, and C/EBP family members [10].
Retro- and lentiviral vectors have been widely used for
gene delivery to human hematopoietic stem/progenitor
cells [11]. A major problem with Moloney murine
leukemia virus (MoMLV)-based vectors is their low
transduction efﬁciency, due to the reduced expression of
the corresponding cellular receptors. This problem was
resolved by the application of a pseudo-typed envelope
protein from RD114, a feline endogenous retrovirus [12].
Another problem involves silencing the promoter activity
of its long terminal repeat (LTR) in primitive stem cells
[13]. The use of the LTR from murine stem cell virus
(MSCV) [14] or myeloproliferative sarcoma virus (MPSV)
[15] facilitated a more stable expression of foreign genes,
both in vitro and in vivo. Eventually, bicistronic, MSCV-
based retroviral vectors expressing enhanced green ﬂuo-
rescent protein (EGFP) were developed that could
effectively transduce murine [16] and human [17] stem/
progenitor cells. One report described a series of retroviral
vectors, including pMXs-Ig, pMYs-Ig, and pMCs-Ig,
together with a novel packaging cell line, Plat-F, which
generates the RD114 envelope protein [18].
In the present study, we assessed these three retroviral
vectors for their ability to transduce human CBCD34
+ cells
and to stably express a foreign gene during differentiation
toward B-lymphoid and myeloid lineages using a coculture
system with HESS-5 cells. We showed that a single 24-h
infection was sufﬁcient for these vectors to transduce
CBCD34
+ cells and to achieve stable expression of the
foreign gene. Furthermore, we examined the effects of the
ectopic expression of Pax5 in early B-lymphoid and mye-
loid progenitors.
2 Materials and methods
2.1 Preparation of CD34
+ cells from human umbilical
cord blood (CB)
Umbilical CB units were collected from single-birth, full-
term, normal deliveries following the standards for CB
collection developed by the Tokyo Cord Blood Bank and
the Institute of Medical Science, University of Tokyo.
CD34
+ cells were puriﬁed from mononuclear cells using a
CD34
+ Progenitor Cell Isolation kit and a MiniMACS
separation unit (Miltenyi Biotec GmbH, Glandbach,
Germany) and were stored frozen until use. Samples with
CD34
+-cell purity and viability of at least 95% were used
for experiments.
2.2 Cell culture
The murine stromal cell line, HESS-5, was maintained in
DNA, RNA-free alpha Modiﬁed Eagle’s Medium (a-MEM;
12561-056; Gibco, Grand Island, NY) supplemented with
10% (v/v) horse serum. Only HESS-5 cells below passage
30 were used in coculture experiments. Plat-F cells were
cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), containing puromycin (1 mg/mL) and brastcidine
(10 mg/mL). All cells were cultured in a humidiﬁed 5%
CO2 atmosphere at 37C.
2.3 Culturing CBCD34
+ cells on a murine stromal
layer
HESS-5 cells were prepared at 2 9 10
4 cells/well in a
6-well plate, 1 week prior to seeding CD34
+ cells, and
were allowed to reach conﬂuence without irradiation.
CD34
+ cells were plated at a density of 3 9 10
3 cells/well
onto the HESS-5 cell layer in 3 mL of a-MEM containing
10% heat-inactivated FBS with recombinant human stem
cell factor (SCF, 20 ng/mL) and recombinant human
granulocyte colony-stimulating factor (G-CSF, 10 ng/mL).
The coculture medium was removed and replenished with
fresh medium every week for up to 9 weeks. Non-adherent
cells in the medium were collected. Each week, one well of
cocultures was harvested, separating non-adherent and
migrating cells beneath the HESS-5 cell layer for RNA
extraction and ﬂow cytometry (FCM).
2.4 Microscopic and ﬂow cytometric analysis
Non-adherent cells were harvested from the culture med-
ium. After removing the non-adherent cells, adherent cells
were separated in phosphate-buffered saline (PBS) con-
taining 5 mM EDTA. Cells were resuspended in PBS (-)
containing 2 mM EDTA and 2% FBS and counted by
trypan blue dye exclusion. Non-adherent cells (myeloid
cells) from the culture medium or adherent cells (B-lym-
phoid cells) were centrifuged on glass slides using a
cytospin centrifuge and stained for 5 min in May–Grun-
wald solution and 20 min in Giemsa solution before being
analyzed under a microscope (ECLIPSE E600; Nikon,
Tokyo, Japan). Photographs of cytospin smears were cap-
tured with an Olympus BX51 microscope (Olympus,
Tokyo, Japan) equipped with a 609 objective lens,
Olympus DP70 CCD camera, and Sysmex LAFIA picture
ﬁling system (Sysmex Corp., Kobe, Japan). Cells were then
passed through a 40-mm nylon-mesh ﬁlter and labeled with
a combination of FITC-CD19 and PE-CD34, FITC-CD20
and PE-CD19, FITC-lambda- and PE-kappa-labeled mono-
clonal antihuman antibodies (BD Pharmingen, San Diego,
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123CA, USA). The monoclonal antihuman antibodies were
ﬁrst tested for the absence of detectable cross-reactivity
with HESS-5 cells. Two-color FCM was performed using a
FACS Caliber ﬂow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA) with Cell Quest acquisition software (BD
Pharmingen). List mode ﬁles were analyzed with the
FlowJo software (Tree Star Inc., Ashland, OR, USA).
2.5 Reverse-transcription polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from CBCD34
+ cells and non-
adherent and adherent cells cocultured for 1–8 weeks using
the RNeasy micro kit (Qiagen, Valencia, CA, USA). Total
RNA (200 ng) from each sample was reverse-transcribed
using the SuperScriptII First-strand Synthesis System
(Invitrogen, Carlsbad, CA, USA) and oligo (dT) primer,
resulting in 20 lL of RT products. Full-length human E2A,
EBF, Pax5 and RAG2, the N-terminal fragment of RAG1,
and the C-terminal fragment of RAG1 cDNAs were
ampliﬁed from 2 lL of the RT products, using a high
ﬁdelity PCR kit (Takara Syuzo, Otsu, Japan) and the fol-
lowing primers:
E2A (forward 50-GAGAATGAACCAGCCGCAGAG
GATG-30 and reverse 50-TTCACATGTGCCCGGCGGGG
TTGTG-30); EBF (forward 50-TTTCATGTTTGGGATT
CAGGAAGC-30 and reverse 50-TTCACATAGGAGGAA
CAATCATGCC-30); Pax5 (forward 50-ATGGATTTAGA
GAAAAATTATCCG-30 and reverse 50-TCAGTGACGG
TCATAGGCAGTG-30); N-RAG1 (forward 50-TGCCGCA
TCTGTGGGAATTCTTTT-30 and reverse 50-CTGAGCT
CCTTCTCTTGCGCTGACG-30); and C-RAG1 (forward
50-CCAGCTGTTTGCTTGGCCATGCGT-30 and reverse
50-TTGGGATCTCATGCCTTCCAAGAT-30). The result-
ing PCR products [E2A 1,970 base pairs (bp), EBF
1,776 bp, Pax5 1,470 bp, RAG2 1,561 bp, N-RAG1
154 bp, C-RAG1 331 bp] were cloned into the pCR-
BluntII cloning vector (Invitrogen), and sequenced using
the BigDye terminator cycle sequencing kit and an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). These plasmids were then used as
controls in the quantitative, real-time PCR.
2.6 Quantitative RT-PCR (QR-PCR) analysis
Quantitative analysis of mRNA expression was performed
using 2 lL of the RT product per reaction, the TaqMan
Universal PCR Master Mix (Applied Biosystems), human
gene-speciﬁc primers, and 50-FAM- and 30-TAMRA-
labeled probes (Table 1), according to the manufacturer’s
instructions. Each reaction was performed in duplicate. The
speciﬁed genes were ampliﬁed for 50 cycles, and PCR
reactions were analyzed with an ABI Prism 7700 (Applied
Biosystems). Quantiﬁcation of E2A, EBF, Pax5, and
RAG1 gene expression in each sample was accomplished
by the relative standard curve method, normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA as an internal RNA standard [19]. We conﬁrmed
the efﬁciency of the PCR reactions and the threshold cycle,
calculated with a standard curve generated from serially
diluted (10-fold diluted from 10
6 to 10
1 copies) control
plasmids.
2.7 Construction and production of, and infection
with, retroviral vectors
Plat-F packaging cells were transiently transfected with
pMXs-Ig, pMYs-Ig, and pMCs-Ig using the FuGENE 6
transfection reagent (Roche, Basel, Switzerland). Retrovi-
ral supernatants were harvested 72 h after transfection. The
viral titer of each supernatant, determined by terminal
dilution with CBCD34
+ cells, was nearly 1.5 9 10
6
infectious units/mL.
CBCD34
+ cells were precultured for 24 h in the con-
ditioning medium: Iscove’s Modiﬁed Dulbecco’s Medium
(IMDM) with 20% FBS, SCF (50 ng/mL), Flt-3 ligand
(Flt-3L, 50 ng/mL), thrombopoietin (TPO, 10 ng/mL), and
interleukin-3 (IL-3, 10 ng/mL). Infection of CBCD34
+
cells was performed in Retronectin (CH-296; Takara
Shuzo)-coated, 24-well plates. An aliquot of 2 9 10
5
Table 1 Primers and probes for quantitative RT-PCR
NCBI-
GeneID
Forward primer (50–30) Probe (50–30) Reverse primer (50–30) Amplicon
(bp)
E2A 6929 AGGGCACCCACTTCACTGAG CGCACAGCAGCCTCTCTTCATCCA GAGTCCCGGTCCCAGGAAT 65
EBF 1879 GATACGGCTCTGCCGCAAT TCCAATTTGGGCGGCTCCCC CAGCTGAGCCGTTGAGGAAG 63
RAG1 5896 TTTACTTCCCGAGGAACGTGA ATGGAGTGGCACCCCCACACACC GGGCAGTGTTGCAGATGTCA 72
Pax5 5079 TACTCAGCACCGACGC ATTCCTCGTACAACGACTCCTGGAGGTTCC GCGGCAGCGCTATAAT 149
GAPDH
2597
GAAGGTGAAGGTCGGAGTC CAAGCTTCCCGTTCTCAGCC GAAGATGGTGATGGGATTTC 226
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123precultured CD34
+ cells was cultured in 1.3–1.5 mL of
viral supernatant for 24 h. The cytokine conditions corre-
sponded to the preculture medium, except for the presence
of additional protamine (5 mg/mL). For experiments with
the pMCs-Ig and Pax5 vectors, fresh viral supernatant was
replaced 49 during the 48-h infection with cytokines and
protamine (5 mg/mL) at the same concentration.
2.8 Cell sorting, coculture, and colony-forming assay
Infected CBCD34
+ cells were sorted into EGFP-positive
and -negative fractions using a FACS Aria cell sorter (BD
Pharmingen). Then, 9 9 10
3 EGFP
+ cells were subjected
to a coculture assay, and 9 9 10
2 EGFP
+ cells were used in
a colony-forming assay. EGFP
+ cells were seeded onto a
HESS-5 monolayer in triplicate and cultured for
6–9 weeks, as mentioned above. Cocultures were observed
every week under an inverted Nikon TMD300 microscope
with a ﬂuorescence light unit. Photomicrographs were
captured using the same microscope equipped with a 209
objective lens and a Nikon DXM1200 digital camera sys-
tem. The total medium volume was changed at weekly
intervals, and all non-adherent cells were collected and
subjected to cell count and ﬂow cytometric analysis. On
day 42, all cocultured cells were harvested with PBS (-)
containing 0.5% BSA and 5 mM EDTA and subjected to
similar analysis. Cells were stained with a combination of
PE-CD33 and APC-CD19, PE-CD20 and APC-CD19, and,
PE-kappa and APC-CD19, and analyzed by three-color
FCM. The colony-forming assay was carried out in tripli-
cate in 35-mm Petri dishes by incubating 3 9 10
2 EGFP-
positive cells in 1 mL METHOCULT H4435 (Stem Cell
Technologies, Vancouver, BC, Canada) containing eryth-
ropoietin (EPO, 3 U/mL), SCF (50 ng/mL), GM-CSF
(20 ng/mL),IL-3(20 ng/mL),interleukin-6(IL-6,20 ng/mL),
and G-CSF (20 ng/mL). The colony number was calculated
on days 12–14 of culture. Pax5 experiments were indepen-
dently performed 39.
2.9 Cell cycle analysis and apoptosis assay
To assess the cell cycle, collected cells were ﬁxed with
cooled 70% ethanol. The ﬁxed cells were washed twice
with PBS (-) and incubated with 0.25 mg/mL ribonucle-
ase A for 30 min. The 4-week cultured cells were ﬁxed
with IntrePrep
TM Permeabilization Reagent 1 (Immuno-
tech, Marseille, France) containing 5.5% formaldehyde and
permeabilized with Reagent 2 containing 0.001% saponin
and 0.25 mg/mL ribonuclease A for 30 min according to
the instructions. Subsequently, propidium iodide (ﬁnal
concentration, 50 lg/ml) was added to each sample to stain
DNA. For the detection of apoptosis, collected cells were
stained with an Annexin V–PE Apoptosis Detection Kit
(BD Biosciences, San Diego, CA, USA) according to the
instructions. Each sample was analyzed by ﬂow cytometry.
The cell cycle and population of apoptotic cells were
analyzed using FlowJo software (TreeStar, San Carlos, CA,
USA).
3 Results
3.1 Cellular and molecular characteristics of B-cell
differentiation in vitro
When CBCD34
+ cells were cultured on HESS-5 cells, the
number of non-adherent myeloid cells increased after
2 weeks, reaching a maximum during the third week, and
decreasing thereafter. In adherent cell layers, deﬁnite foci
of small B-lymphoid cells beneath the stromal layer
appeared during the second week and increased in size
until the sixth week. At ﬁrst, B-lymphoid progenitors
developing in the coculture system were characterized by
surface marker analysis and the quantitative measurement
of B-cell-speciﬁc gene expression. Non-adherent or loosely
adherent CD33
+ myeloid cells were washed out before
harvesting cells from the culture. CD34
+CD33
- cells could
be observed as single cells beneath the stromal layer during
the ﬁrst week of culture, and formed colonies of 10–20
cells during the second week (data not shown). On day 21,
CD34
+CD19
- cells comprised 20% of the CD33
- cell
population, and a comparable proportion of CD34
+CD19
+
proB and CD34
-CD19
+ preB cells appeared in the culture.
They differentiated into smaller CD34
-CD19
+CD20
+ late
preB cells on day 28. On day 42, more than 10% of the
adherent lymphoid cells expressed immunoglobulin (Ig)
light chains, suggesting the appearance of immature B-cells
(Fig. 1a).
Next, B lymphoid cells adherent to or beneath the
HESS-5 layer were harvested weekly from days 1–49, and
total RNA was extracted for QR-PCR analysis of B-cell-
speciﬁc transcripts including E2A, EBF, Pax5, and RAG1.
The vast majority of the initial cells were CD34
+CD19
-,
and, at this stage, all transcripts could be detected. The
expression levels of both E2A and RAG1 were relatively
high throughout the culture period. In contrast, EBF was
weakly expressed in the early stage and upregulated after
14 days of culture. Pax5 was initially expressed at a very
low level, but was signiﬁcantly upregulated after 14 days
of culture, before which a transient down-regulation of
E2A and RAG1 transcripts was observed. The expression
levels of EBF and Pax5 were comparable in the middle and
late phases of culture, but were still 10-fold lower than that
of E2A (Fig. 1b).
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1233.2 Retroviral transduction of CBCD34
+ cells
The three retroviral vectors used in this study have been
described elsewhere [18]; a schematic representation of the
constructs is shown in Fig. 2. To compare the transduction
efﬁciency of these vectors, we prepared[95% pure human
CBCD34
+ cells. Cytokine-stimulated CD34
+ cells were
infected for 24 h with pMXs-Ig, pMYs-Ig, or pMCs-Ig
[multiplicity of infection (MOI) = 10]. The cell viability
was typically [95%. The transduction efﬁciency was
comparable among the three vectors, and was typically
[60% at the end of infection. The percentage of CD34
+
cells showed no change between before and after viral
infection (Fig. 3a).
Infected CD34
+ cells were immediately seeded onto
conﬂuent HESS-5 cells. Four days later, the EGFP
+ cell
population in CD33
+ cells increased to 82.6% (pMXs),
88.2% (pMYs), and 88.5% (pMCs), and the mean ﬂuores-
cence intensity (MFI) of EGFP was 209, 760, and 537,
respectively. Repeat experiments conﬁrmed that the
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Fig. 1 a Sequential phenotypic
analysis of in vitro B-cell
differentiation examined by
ﬂow cytometry of CD34, CD19,
CD20, and light chain (kappa or
lambda) expression. The
quadrate gate of two-color
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b Kinetic analysis of
B-lymphopoiesis-associated
gene expression by QR-PCR for
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The results are the mean ± SD
of duplicate experiments
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123intensity of EGFP expression in CD33
+ cells was in this
order (Fig. 3b). After 28 days of culture, most of the non-
adherent myeloid cells resembled mature neutrophilic
granulocytes, and small B-lymphoid cells formed numerous
cobblestone areas beneath the HESS-5 layer. Up to this
stage, the percentage of EGFP
+ cells was always over 80%
throughout the culture, regardless of the cell lineage or type
of retroviral vector. The MFI of EGFP in granulocytes
transduced with pMXs, pMYs, and pMCs was 131, 676, and
501, respectively (Fig. 3c, upper panel). The MFI of EGFP
in late preB cells transduced with pMXs, pMYs, and pMCs
was 134, 198, and 208, respectively (Fig. 3c, lower panel).
Thus, the promoter activity of each retroviral vector was
sensitive to the developmental stage and/or cell lineage.
3.3 Sustainability of EGFP expression during B-cell
and granulocytic differentiation in vitro
Based on the comparative data between the three retroviral
vectors, further experiments were conducted using pMCs-
Ig, as it provided adequate expression of the foreign genes
in both B-lymphoid, myeloid, and progenitor cells. To
improve the transduction efﬁciency of CD34
+ cells, cyto-
kine-treated CD34
+ cells were infected with fresh viral
supernatant at 12-h intervals during the 48 h. The
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Fig. 2 Structure of pMXs-Ig, pMYs-Ig, and pMCs-Ig retrovirus
vectors. w packaging signal, D gag truncated gag sequence, LTR long
terminal repeat, MCS multi-cloning site, IRES internal ribosomal
entry site, EGFP enhanced green ﬂuorescent protein, white box Mo-
MLV LTR, gray box PCMV LTR, hatched box MPSV LTR
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Fig. 3 a The relationship
between EGFP expression and
the surface marker CD34 at the
end of infection. Cells were
stained with PE-conjugated
anti-CD34 and analyzed by
two-color FCM. b After a 4-day
coculture, EGFP expression
levels in CD33
+ cells were
compared between the three
vectors by FCM, and cytospin
preparations revealed an
immature myeloid cell
morphology. The photograph of
pMCs-Ig cells shown is
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Coculture at 28-days.
Constitutive EGFP expression
by pMXs, pMYs, and pMCs in
mature myeloid cells (upper
panels), and B-lymphoid cells
(lower panels). The photograph
of pMCs-Ig cells is
representative (9600)
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123transduction efﬁciency, evaluated by the percentage of
EGFP
+ cells after ﬁnal infection, increased to 80.4 ± 6%;
meanwhile, the percentage of CD34
+ cells decreased to
75.8 ± 2.7%. The EGFP
+ cells represented 86.3 ± 4.6%
of CD34
+ cells at the end of the infection procedure
(n = 3; Fig. 4a).
Next, EGFP
+ cells were sorted on a FACS (pur-
ity[98%) and seeded onto the HESS-5 layer. An aliquot
of sorted cells was subjected to a methylcellulose colony-
forming assay. Cloning efﬁciency was 147.9 ± 15
colonies/300 cells (n = 3). In coculture experiments, we
monitored EGFP expression by FCM at 1, 6, and 9 weeks
of culture to assess the sustainability of pMCs-mediated
gene expression. After 1 week, almost all non-adherent
myeloid cells were positive for EGFP. Furthermore,
adherent CD19
+ small preB cells stably expressed EGFP
after 6 and 9 weeks, while a two-peaked expression pattern
was noted on day 42. Accordingly, pMCs-mediated gene
expression was maintained at a high level over 9 weeks of
culture (Fig. 4b).
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Fig. 4 a Transduction rates
evaluated by the percentage of
EGFP
+ cells and percentage of
CD34
+ cells after 49 repeat
infection. The mean
transduction rate and SD were
80.4 ± 6%, the mean
percentage of CD34
+ cells
decreased to 75.8 ± 2.7%, and
the percentage of EGFP
+ cells
in the CD34-positive gate was
86.3 ± 4.6% (n = 3). The data
shown are from one
representative experiment of
three. b The stability of EGFP
expression in pMCs-Ig-
transduced cells was determined
after 1, 6, and 9 weeks of
coculture. Non-adherent cells in
the culture medium on day 7
(upper). Almost all cells were
developing into CD33
+ myeloid
cells. All of the cocultured cells
were trypsinized on day 42
(middle) and day 63 (lower),
developing into CD19
+ B-
lymphoid cells. In each case, the
percentage of EGFP
+ cells
determined by FACS was above
98%
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1233.4 Disruption of B lymphopoiesis and myelopoiesis
by the Pax5 transgene
A combination of retroviral gene transfer to CBCD34
+
cells with the HESS-5 coculture system allowed us to
simultaneously engineer both B-cell and myeloid progen-
itors. Pax5 is essential for B-cell-speciﬁc gene expression
such as CD19, and is indispensable throughout the early
stages of B-cell differentiation [5]. In addition, a subset of
acute myeloid leukemia cells harboring t(8;21) transloca-
tion frequently express both Pax5 and CD19, suggesting
the possible involvement of ectopic Pax5 expression in
myeloid leukemogenesis [20, 21]. Therefore, we focused
on the impact of the Pax5 transgene on the growth and
bilineage differentiation of CBCD34
+ cells.
After infection with pMCs–Pax5-Ig or pMCs-Ig, sorted
EGFP
+ cells were subjected to the standard colony-forming
and coculture assays with HESS-5 cells. Colony-forming
assays showed that total plating efﬁciency of control pro-
genitors was 147.9 ± 15/300 cells, as described above, but
that Pax5-transduced progenitors produced only 33 ± 1.8
colonies/300 cells. CFU-GM-derived colony formation was
inhibited by up to 50% compared to the control, and, sur-
prisingly, CFU-Mix/BFU-E-derived colony formation was
almost completely inhibited by the Pax5 transgene
(Fig. 5a).
In the coculture system, the entire medium containing
non-adherent and loosely attached cells was harvested
weekly for cell counting, and an equal volume of fresh
medium was added. Changes in the non-adherent cell
number are shown in Fig. 5b. In the control culture, the
number of non-adherent cells reached a maximum during
the third week and gradually decreased thereafter. In the
Pax5-transduced culture, the cell number was markedly
reduced and almost negligible after 4 weeks. Non-adherent
cells after 1 week in the control culture consisted of vari-
ous differentiation stages of myeloid cells with a normal
appearance. In contrast, Pax5-transduced cells consisted
primarily of immature, dysplastic myeloid cells and also
contained slightly dysplastic neutrophils (Fig. 5c).
On day 7, Pax5-transduced adherent cells were fewer in
number and smaller in size than control cells. After
6 weeks of coculture, the difference in the adherent cell
number became much larger. In the control culture, small
B-lymphoid cells vigorously proliferated and formed
massive cobblestone areas beneath the HESS-5 layer,
whereas, in the Pax5-transduced culture, adherent cells
were sparse and did not form any deﬁnite cobblestone area
(Fig. 5d). The total number of adherent cells was
15.5 ± 0.65 9 10
5 cells in the control culture and
0.65 ± 0.26 9 10
5 cells (5.2 ± 3.8% of the control) in the
Pax5-transduced culture (Fig. 5e). However, the remaining
Pax5-transduced cells expressed CD20 and the Ig light
chain at rather higher levels than control cells, suggesting
intact maturation (Fig. 5f).
During the ﬁrst 3 weeks of coculture, cell cycle analysis
of the infected cells, most of which had differentiated into
myeloid cells, showed that the G2/M population of the
Pax5-transduced culture was nearly equal in size to that of
the control. Meanwhile, the ratio of apoptotic cells in the
Pax5-transduced culture gradually increased compared
with that in the control culture (Fig. 6a). In spite of the
sorting procedure prior to coculture, contaminated, non-
transduced cells became dominant after 4 weeks. The
percentage of EGFP
+ cells in the Pax5-transduced culture
was 80% in the ﬁrst week, but decreased to 50% in the
fourth week (data not shown). Consequently, we conducted
two-color analysis of the 4-week cultured cells using In-
traPrep
TM Permeabilization Reagent, which allows the
retention of cytosolic EGFP and PI-based DNA staining.
Cell cycle analysis of developing lymphoid cells showed
that the G2/M population in the Pax5-transduced culture
was nearly equal in size to that of the control. However, the
ratio of apoptotic cells in the Pax5-transduced culture
increased slightly as compared with that in the control
culture (Fig. 6b).
4 Discussion
The detection and tracking of genetically manipulated
human B-lymphoid progenitors in vitro not only promotes
our understanding of the physiological mechanisms
underlying human B-cell development, but will also aid in
elucidating the pathological processes involved in con-
genital and acquired disorders. Information on early B
lymphopoiesis in humans substantially lags behind that in
mice, and important differences exist between the two
species. For example, interleukin-7 can support this process
in mice [22, 23], but not in humans [24, 25]. No combi-
nation of cytokines has been identiﬁed that stimulates
human B-cell production in culture. Thus, the most effec-
tive models for human B lymphopoiesis employ murine
stromal cells, which provide, as yet, uncharacterized
stimuli [26].
CBCD34
+ cells are heterogeneous, and most of them
express CD33. Early B-lymphoid progenitors are included
in a CD34
+CD33
-CD19
- minor fraction. Because E2A is
commonly expressed in early B-lymphoid [27] and mye-
loid progenitors of rats [28] and mice [29], its high-level
expression on day 1 in CD34
+ cells is reasonable. In
murine experiments, EBF is primarily expressed around the
proB cell stage, and Pax5 can be seen from the late proB to
mature B-cell stage [30]. Their low level of expression
during the ﬁrst 2 weeks of culture seems to reﬂect the quite
rare population in this stage among CB progenitors.
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Fig. 5 a White box total
number of control colonies,
black box total number of Pax5
colonies, slanted box BFU-E
colony plus mixed colony
numbers, gray box CFU-GM
colony number. Three hundred
control and Pax5 cells were
seeded, and the colony number
was counted 14 days later (the
data shown are representative of
four independent experiments).
b The total weekly number of
non-adherent cells, control cells
(open circles) versus Pax5 cells
(ﬁlled circles). The number of
Pax5 cells was consistently
lower than that of control cells.
c Surface marker and
morphology of myeloid cells
after 1 week of coculture.
EGFP
+ myeloid cells were
stained with PE-CD33 and
APC-CD19 and examined by
three-color FCM. A minor but
signiﬁcant fraction of non-
adherent cells could be detected
in the lymphoid gate of the cell
population transduced with
Pax5 vector, but not the control
vector. M-G-stained cytospin
preparations revealed the
myelogenetic maturation arrest
of Pax5 cells (9600). One
representative result of three
repeat experiments is shown.
d Image capture with an
inverted Nikon TMD300
microscope after 1 and 6 weeks
of coculture (9400). The
cobblestone area generated by
Pax5 cells was markedly
reduced. e Total cell number of
control and Pax5 cells on day 42
(n = 3). f Living EGFP
+ cells
from the Pax5-transduced
CD34
+ cells expressed CD20 at
a higher level than the control.
A small number of EGFP
+ cells
also expressed the kappa light
chain (these data are
representative of three
independent experiments)
Efﬁcient retroviral transduction of human B-lymphoid and myeloid progenitors 359
123However, RAG1 is expressed as early as in common
lymphoid progenitors, transiently down-regulated after
completion of the IgH gene rearrangement in the proB cell
stage, and upregulated again at the preB cell stage, until
completion of the IgL gene rearrangement [31, 32]. Based
on our data from FCM and QR-PCR, human B lympho-
poiesis simulated in vitro occurs as follows: before day 14,
most B-lymphoid progenitors are in the pre-proB cell or
earlier stages. Around day 21, mixed populations of proB
and large preB cells occur. After day 28, small preB cells
are increasing, and, on day 42, immature B-cells are
developing. This is consistent with the report of Fluckiger
et al. 33] who showed that the development of surface
IgM
+ immature B-cells delimited the differentiation stage
in a coculture system. Despite such a restriction, the
present coculture system is a unique and suitable procedure
for analyzing the early B lymphopoiesis in humans.
We veriﬁed the efﬁcient retroviral transduction of both
B-lymphoid and myeloid progenitors and stable expression
of the foreign gene during their differentiation. We tested
three types of vector containing different LTR sequences.
Although the expression level of EGFP mediated by each
vector was comparable in primary CD34
+-cell populations,
pMXs-mediated EGFP expression was more prominently
reduced in myeloid and B-lymphoid cells compared to
pMYs and pMCs. The use of Plat-F packaging cells
facilitated a [85% transduction efﬁciency with a single
24-h infection protocol and [90% with a 49-repeated
infection protocol. Additionally, an adequate EGFP
expression level was maintained in transduced cells for up
to 9 weeks of culture. It has been reported that pMXs-
mediated gene expression, and possibly pMYs (MSCV),
was down-regulated in mature blood cells including ery-
throid, myeloid, and B-lymphoid cells after an in vivo,
long-term BM repopulation [14]. Collectively, a combi-
nation of pMCs-Ig and Plat-F is valuable for genetically
engineering human CD34
+ cells and their progeny in vitro.
Using this system, we examined whether ectopic Pax5
expression in CBCD34
+ cells would interfere with myeloid
cell commitment and/or accelerate B-cell differentiation.
Chiang and Monroe [34] showed that Pax5 inhibited the
expansion of myeloid progenitors by suppressing their
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123response to myeloid growth factors and by directing mul-
tipotent progenitors toward the B-cell lineage in vitro. Cotta
et al. [35] reported that Pax5 is not sufﬁcient to block
myeloid development in vivo when ectopically expressed in
primitive, multipotent progenitors. Recently, Anderson
et al. [36] demonstrated that the ectopic expression of Pax5
in multipotent stem/progenitor cells generated B220
+Gr1/
Mac1
+ biphenotypic progenitors, which sustained the long-
term generation of myeloid progenitors in vitro and
remained capable of myeloid differentiation. All of these
studies were performed on murine stem/progenitor cells,
and did not refer to the impact of the Pax5 transgene on
inhibiting B-cell development. Our data indicated that Pax5
markedly inhibited myelopoiesis. Speciﬁcally, the clonal
growth of common myeloid (CFU-Mix) and early erythroid
(BFU-E) progenitors was almost completely inhibited. In
the coculture assay, granulocytic differentiation during the
ﬁrst week was partially arrested. CD19 expression could be
induced by Pax5 in a signiﬁcant portion of immature
myeloid cells, as was described in our previous report [37],
and these cell populations rapidly disappeared from the
culture. Assuming that these populations were human
counterparts of B220
+Gr1/Mac1
+ biphenotypic progenitors,
our culture conditions were not optimized to support their
survival. Additionally, we examined the development of
these biphenotypic progenitors in a lymphoid-directed
cytokine condition [36] with HESS-5 support. The per-
centage of biphenotypic progenitors increased up to 70% in
the second week, but we could not maintain them for more
than 3 weeks (data not shown). We hypothesize that ectopic
Pax5 may induce CD19 expression in myeloid progenitors
and maintain its expression during the early phase of
granulocytic differentiation. However, the differentiation of
Pax5
+ myeloid cells seems to be blocked at the promyelo-
cytic stage, and may undergo apoptosis instead of terminal
differentiation. The results of cell cycle analysis and
apoptosis assay support this hypothesis.
Although the mechanism by which Pax5 inhibits mye-
lopoiesis is unknown, cross-talk appears to occur between
Pax5 transcription factors, including GATA and C/EBP
family members [10], among which Pax5 is likely to be
associated with PU.1 [38], a transcription factor essential
for myelopoiesis. The entrapment of PU.1 by ectopic Pax5
in myeloid progenitors may interfere with their growth and
differentiation.
One of the unexpected ﬁndings of this study was the
marked inhibition of B lymphopoiesis by ectopic Pax5. In
the cell cycle analysis and apoptosis assay, ectopic Pax5-
transduced B-lymphoid cells generated similar results to
control cells. Inhibition apparently occurred during the ﬁrst
week of culture, when the expression of endogenous Pax5
was barely detectable but E2A was strongly expressed. The
reduced number of early B-cell progenitors may decrease
the production of B-cells without the impairment of dif-
ferentiation. A deﬁned hierarchy exists within B-cell-
speciﬁc transcription factors, and endogenous Pax5 is
induced by a coordinated action of E2A and EBF.
Although we could not examine changes in the expression
of endogenous transcription factors brought about by
ectopic Pax5, negative feedback may occur from Pax5 to
E2A, resulting in the impairment of further B-cell devel-
opment. The conditional expression of Pax5, for example,
by the use of estrogen receptor fusions during B-cell dif-
ferentiation in combination with single cell sorting, will
likely be required to examine the precise mode of action of
ectopic Pax5. Nevertheless, this is the initial study to report
the consequences of forced Pax5 expression in human
hematopoietic progenitors.
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